Given the expected increase in the number of people with dementia in the coming years, it is anticipated that the resources necessary to support those with dementia will significantly increase. There will therefore likely be increased emphasis on how best to use limited resources across a number of domains including prevention, diagnosis, treatment and supporting informal caregivers. There has been increasing use of economic methods in dementia in the past number of years, in particular, cost-of-illness analysis and economic evaluation. This paper reviews the aforementioned methods and identities a number of methodological issues that require development. Addressing these methodological issues will enhance the quality of economic analysis in dementia and provide some useful insights about the best use of limited resources for dementia.
Ahmadi-AbhariS.Guzman-CastilloM.BandoszP.ShipleyM. J.Muniz-TerreraG.Singh-ManouxA., … BrunnerE. J. (2017).
Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: Modelling study. BMJ,
358, j2856.
2.
AkobunduE.JuJ.BlattL.MullinsC. D. (2006).
Cost-of-illness studies: A review of current methods. Pharmacoeconomics,
24(9), 869–890.
3.
Alzheimer’s Disease International. (2010). World Alzheimer report 2010: The global economic impact of dementia.
London, England:
Alzheimer’s Disease International.
4.
AngelisA.TordrupD.KanavosP. (2015).
Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy,
119(7), 964–979.
5.
AnkriJ.BeaufilsB.NovellaJ. L.MorroneI.GuilleminF.JollyD., … BlanchardF. (2003).
Use of the EQ-5D among patients suffering from dementia. Journal of Clinical Epidemiology,
56(11), 1055–1063.
6.
BehrensC.HenkeK. (1988).
Cost of illness studies: No aid to decision making: Reply to Shiell et al. (Health Policy, 8 (1987) 317–323). Health Policy,
10(2), 137–141.
7.
BloomD.CafieroE.Jané-LlopisE.Abrahams-GesselS.BloomL. R.FathimaS., … O’FarrellD. (2011). The global economic burden of noncommunicable diseases.
Geneva, Switzerland:
World Economic Forum.
8.
BrooksR. (1996).
EuroQol: The current state of play. Health Policy,
37(1), 53–72.
ChariA. V.EngbergJ.RayK. N.MehrotraA. (2015).
The opportunity costs of informal elder-care in the United States: New estimates from the American time use survey. Health Service Research,
50(3), 871–882.
11.
ChesterH.ClarksonP.DaviesL.SutcliffeC.DaviesS.FeastA., … Home Support in Dementia. (2018).
People with dementia and carer preferences for home support services in early-stage dementia. Aging & Mental Health,
22(2), 270–279.
12.
ClaxtonK.MartinS.SoaresM.RiceN.SpackmanE.HindeS., … SculpherM. (2013). Methods for the estimation of the NICE cost effectiveness threshold (CHE Research Paper 81). York, England: University of York.
13.
CodurasA.RabasaI.FrankA.Bermejo-ParejaF.López-PousaS.López-ArrietaJ. M., … RejasJ. (2010).
Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer’s disease type in Spain: The ECO study. Journal of Alzheimer's Disease,
19(2), 601–615.
14.
ComansT. A.NguyenK. H.MulhernB.CorlisM.LiL.WelchA., … RatcliffeJ. (2018).
Developing a dementia-specific preference–based quality of life measure (AD-5D) in Australia: A valuation study protocol. BMJ Open,
8(1), e018996.
15.
ConnollyS.GillespieP.O’SheaE.CahillS.PierceM. (2014).
Estimating the economic and social costs of dementia in Ireland. Dementia (London),
13(1), 5–22.
16.
CookseyD. (2006). A review of UK health research funding.
London, England:
HMSO.
17.
CoucillW.BryanS.BenthamP.BuckleyA.LaightA. (2001).
EQ-5D in patients with dementia: An investigation of inter-rater agreement. Medical Care,
39(8), 760–771.
18.
CurrieG.KerfootK. D.DonaldsonC.MacarthurC. (2000).
Are cost of injury studies useful?Injury Prevention,
6(3), 175–176.
19.
D’AmicoF.RehillA.KnappM.AguirreE.DonovanH.HoareZ., … WhitakerC. (2015).
Maintenance cognitive stimulation therapy: An economic evaluation within a randomized controlled trial. Journal of the American Medical Directors Association,
16(1), 63–70.
20.
DrummondM. (1992).
Cost-of-illness studies: A major headache?Pharmacoeconomics,
2(1), 1–4.
21.
DrummondM.SculpherM.ClaxtonK.StoddartG. L.TorranceG. W. (2015). Methods for the economic evaluation of health care programmes.
Oxford, England:
Oxford University Press.
22.
DrummondM.SculpherM.TorranceG. W.O'BrienB. J.StoddartG. L. (2005). Methods for the economic evaluation of health care programmes.
Oxford, England:
Oxford University Press.
23.
GillespieP.ConnollyS. (2015). The economics of dementia. In CullinanJ.LyonsS.NolanB. (Eds.), The economics of disability: Insights from Irish research, pp. 123–141.
Manchester, England:
Manchester University Press.
24.
HigginsP. (2013).
Involving people with dementia in research. Nursing Times,
109(28), 20–23.
25.
HollowayR. G.RingelS. P. (2011).
Getting to value in neurological care: A roadmap for academic neurology. Annals of Neurology,
69(6), 909–918.
26.
HounsomeN.OrrellM.EdwardsR. T. (2011).
EQ-5D as a quality of life measure in people with dementia and their carers: Evidence and key issues. Value in Health,
14(2), 390–399.
27.
JakobsenM.PoulsenP. B.ReicheT.NissenN. P.GundgaardJ. (2011).
Costs of informal care for people suffering from dementia: Evidence from a Danish survey. Dementia and Geriatric Cognitive Disorders Extra,
1(1), 418–428.
28.
JoC. (2014).
Cost-of-illness studies: Concepts, scopes, and methods. Clinical and Molecular Hepatology,
20(4), 327–337.
29.
JonesC.EdwardsR.KnappM. (Eds). (2016). Economic evaluation in dementia research: Concepts, methods and experiences.
London, England:
Routledge.
30.
JonssonL.AndreasenN.KilanderL.SoininenH.WaldemarG.NygaardH., … WimoA. (2006).
Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Disease & Associated Disorders,
20(1), 49–55.
31.
KarlawishJ. H.ZbrozekA.KinosianB.GregoryA.FergusonA.GlickH. A. (2008a).
Preference-based quality of life in patients with Alzheimer’s disease. Alzheimer's & Dementia,
4(3), 193–202.
32.
KarlawishJ. H.ZbrozekA.KinosianB.GregoryA.FergusonA.LowD. V.GlickH. A. (2008b).
Caregivers’ assessments of preference-based quality of life in Alzheimer’s disease. Alzheimer's & Dementia,
4(3), 203–211.
33.
KnappM.LemmiV.RomeoR. (2013).
Dementia care costs and outcomes: A systematic review. International Journal of Geriatric Psychiatry,
28(6), 551–561.
34.
KnappM.ThorgrimsenL.PatelA.SpectorA.HallamA.WoodsB.OrrellM. (2006).
Cognitive stimulation therapy for people with dementia: Cost-effectiveness analysis. The British Journal of Psychiatry,
188, 574–580.
35.
KrolM.BrouwerW. (2014).
How to estimate productivity costs in economic evaluations. Pharmacoeconomics,
32(4), 335–344.
36.
Luengo-FernandezR.LealJ.GrayA. (2010). Dementia 2010: The economic burden of dementia and associated research funding in the United Kingdom.
Cambridge, England,
Alzheimer’s Research Trust.
37.
Luengo-FernandezR.LealJ.GrayA. M. (2012).
UK research expenditure on dementia, heart disease, stroke and cancer: Are levels of spending related to disease burden?European Journal of Neurology,
19(1), 149–154.
38.
ManghamL. J.HansonK.McPakeB. (2009).
How to do (or not to do) … Designing a discrete choice experiment for application in a low-income country. Health Policy Plan,
24(2), 151–158.
39.
MaxW.WebberP.FoxP. (1995).
Alzheimer’s disease: The unpaid burden of caring. Journal of Aging and Health,
7(2), 179–199.
40.
McDaidD. (2001).
Estimating the costs of informal care for people with Alzheimer’s disease: Methodological and practical challenges. International Journal of Geriatric Psychiatry,
16(4), 400–405.
41.
MillarR.HallK. (2013).
Social return on investment (SROI) and performance measurement. Public Management Review,
15(6), 923–941.
42.
MooreM. J.ZhuC. W.ClippE. C. (2001).
Informal costs of dementia care: Estimates from the National Longitudinal Caregiver Study. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences,
56(4), S219–S228.
43.
MulhernB.RowenD.BrazierJ.SmithS.RomeoR.TaitR., … LampingD. (2013).
Development of DEMQOL-U and DEMQOL-PROXY-U: Generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation. Health Technology Assessment,
17(5), v–xv,1–140.
44.
NaglieG.TomlinsonG.TanseyC.IrvineJ.RitvoP.BlackS. E., … KrahnM. (2006).
Utility-based quality of life measures in Alzheimer’s disease. Quality of Life Research,
15(4), 631–643.
NichollsJ.LawlorE.NeitzertE.GoodspeedT. (2012). A guide to social return on investment.
London, England:
The SROI Network.
47.
OremusM.AguilarS. C. (2011).
A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada. Pharmacoeconomics,
29(2), 141–156.
48.
Pares-BadellO.BarbagliaG.JerinicP.GustavssonA.Salvador-CarullaL.AlonsoJ. (2014).
Cost of disorders of the brain in Spain. PLoS One,
9(8), e105471.
49.
PrinceM.WimoA.GuerchetM. M.AliG. C.WuY-T.PrinaM. (2015). World Alzheimer Report 2015: The global impact of dementia: An analysis of prevalence, incidence, costs and trends.
London, England:
Alzheimer’s Disease International.
50.
QuentinW.Riedel-HellerS. G.LuppaM.RudolphA.KönigH. H. (2010).
Cost-of-illness studies of dementia: A systematic review focusing on stage dependency of costs. Acta Psychiatrica Scandinavica,
121(4), 243–259.
51.
RiceD. P. (1994).
Cost-of-illness studies: Fact or fiction?Lancet,
344(8936), 1519–1520.
52.
RiceD. P.FoxP. J.MaxW.WebberP. A.HauckW. W.LindemanD. A.SeguraE. (1993).
The economic burden of Alzheimer’s disease care. Health Affairs (Millwood),
12(2), 164–176.
53.
RyanM.GerardK.Amaya-AmayaM. (2008). Using discrete choice experiments to value health and health care.
Dordrecht, the Netherlands:
Springer.
54.
SchallerS.MauskopfJ.KrizaC.WahlsterP.Kolominsky‐RabasP. L. (2015).
The main cost drivers in dementia: A systematic review. International Journal of Geriatric Psychiatry,
30(2), 111–129.
55.
ShearerJ.GreenC.RitchieC. W.ZajicekJ. P. (2012).
Health state values for use in the economic evaluation of treatments for Alzheimer’s disease. Drugs & Aging,
29(1), 31–43.
56.
ShiellA.GerardK.DonaldsonC. (1987).
Cost of illness studies: An aid to decision-making?Health Policy,
8, 317–323.
57.
SlaughterS.ColeD.JenningsE.ReimerM. A. (2007).
Consent and assent to participate in research from people with dementia. Nursing Ethics,
14(1), 27–40.
58.
TorranceG.SiegelJ.LuceB. (1996). Framing and designing the cost-effectiveness analysis. In GoldM.SiegelJ.RussellL. B.WiensteinM. C. (Eds.), Cost-effectiveness in health and medicine (pp. 54–81).
New York, NY:
Oxford University Press.
59.
van den BergB.BrouwerW. B.KoopmanschapM. A. (2004).
Economic valuation of informal care. An overview of methods and applications. The European Journal of Health Economics,
5(1), 36–45.
60.
van den BergB.SpauwenP. (2006).
Measurement of informal care: An empirical study into the valid measurement of time spent on informal caregiving. Health Economics,
15(5), 447–460.
61.
WilkinsonH. (2002). The perspectives of people with dementia: Research methods and motivations.
London, England:
Jessica Kingsley.
62.
WillisE.SempleA. C.de WaalH. (2018).
Quantifying the benefits of peer support for people with dementia: A social return on investment (SROI) study. Dementia (London),
17(3), 266–278.
63.
WimoA. (2010).
The art of cost of illness. Journal of Alzheimer’s Disease,
19(2), 617–619.
64.
WimoA.JonssonB.KarlssonG.WinbladB. (Eds). (1998). Health economics of dementia.
Chichester, England:
John Wiley.
65.
WimoA.JonssonL.GustavssonA.McDaidD.ErsekK.GeorgesJ., … ValtonenH. (2011).
The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. International Journal of Geriatric Psychiatry,
26(8), 825–832.
66.
WinbladB.AmouyelP.AndrieuS.BallardC.BrayneC.BrodatyH., … FratiglioniL. (2016).
Defeating Alzheimer’s disease and other dementias: A priority for European science and society. The Lancet Neurology,
15(5), 455–532.
67.
WoodsR. T.OrrellM.BruceE.EdwardsR. T.HoareZ.HounsomeB., … RussellI. (2016).
REMCARE: Pragmatic multi-centre randomised trial of reminiscence groups for people with dementia and their family carers: Effectiveness and economic analysis. PLoS One,
11(4), e0152843.
